BioMarin (BMRN) PT Trimmed at Wedbush Following Briefing Docs; Sees Positive Read-Thru to SRPT, None to PTCT

Buy PTC Therapeutics (PTCT) into the Kyndrisa Advisory Panel Tues - Oppenheimer

Oppenheimer analyst, Christopher Marai, anticipates a narrowly positive BioMarin (NASDAQ: BMRN) Kyndrisa panel outcome, and discussion highlighting key differentiation of PTC Therapeutics (NASDAQ: PTCT) data set, which would reflect positively on the Translarna package.

Key differences set Transarna's package above Kyndrisa... More

BioMarin (BMRN) PT Cut to $100 at Baird; Sees Drisapersen Approval 'Near-Zero'

Baird analyst Brian Skorney reiterated a Neutral rating and lowered his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $100.00 (from $147.00) following Friday's drisapersen FDA riefing documents.

"The documents are in, and they aren't good," Skorney comments. "This comes as no surprise... More

FDA Briefing Docs Offer Positives and Negatives for Sarepta (SRPT) - Baird

Baird analyst, Brian Skorney, published a note this morning highlighting his interpretation of the FDA Briefing Documents on BioMarin's (NASDAQ: BMRN) drisapersen filed Friday. He still believes that Sarepta (NASDAQ: SRPT) has only a 35% chance of getting approval for eteplirsen... More

Despite Harsh BioMarin (BMRN) Briefing Docs, the Jury is Still Out - Leerink Partners

Leerink Partners analyst Joseph Schwartz weighed in on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following today's FDA briefing docs, noting they were even more harsh then expected. That said, the analyst said the jury is still out.

Schwartz commented, "FDA briefing documents for... More

BioMarin (BMRN) Has Good Risk/Reward Despite Cautious FDA Briefing Documents for Drisapersen, Says RBC

BioMarin Pharmaceutical's (NASDAQ: BMRN) long-term positive thesis remains unchanged, said RBC Capital analyst Michael J. Yee. Comments follow the release of FDA advisory committee briefing documents for drisapersen, which were said to have a "cautious tone." While documents appear cautious, Yee thinks approval is possible and risk/reward is good.

"Notably, unlike most panels, the FDA does not specifically ask this panel to vote on the potential approval of the drug so for investors today it's not clear we'll get a great "answer" to satisfy any confidence on the approval debate by... More

BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)

Baird analyst Brian Skorney weighed in on BioMarin Pharma (NASDAQ: BMRN) after today's Drisapersen briefing docs, calling them "ugly"

Skorney commented, "The FDA isn't even offering voting questions to the panelist and the review on risk benefit states: The benefit of drisapersen in exon... More

Pre-Open Stock Movers 11/20: (KBIO) (SRPT) (ANF) Higher; (NMBL) (MENT) (BMRN) Lower (more...)

Nimble Storage (NYSE: NMBL) 46.1% LOWER; reported Q3 EPS of ($0.14), $0.06 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $80.7 million versus the consensus estimate of $87.44 million. Nimble Storage sees Q4 2015 EPS of ($0.11)-($0.13), versus the consensus of $0.00. Nimble Storage sees Q4 2015 revenue of $87-90 million, versus the consensus of $99.20 million. Multiple... More

Sarepta Therapeutics (SRPT) Surges 25% Following BioMarin (BMRN) Briefing Docs

Sarepta Therapeutics (NASDAQ: SRPT) is trading up 25% following BioMarin Pharma's (NASDAQ: BMRN) FDA briefing docs on Drisapersen for treatment of DMD. Meanwhile, BMRN is down 7%.

BioMarin Pharma (BMRN) Announces Consistent Drisapersen Efficacy Evidence Demonstrated Across Three Studies

BioMarin Pharma (NASDAQ: BMRN) announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in comparable patients across three randomized, placebo-controlled studies that were conducted contemporaneously. Kyndrisa is currently under review with U.S. and European health authorities for the treatment of patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. This analysis is included in materials prepared by BioMarin for the November 24, 2015 Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) meeting and can be found on the FDA website at:

BioMarin Pharma (BMRN) Affirms Posting of Drisapersen NDA Briefing Docs

Following earlier reports, BioMarin Pharma (NASDAQ: BMRN) announced that the U.S. Food and Drug Administration (FDA) posted briefing materials... More

FDA Posts Breifing Docs for BioMarin Pharma's (BMRN) Drisapersen

BioMarin Pharma (NASDAQ: BMRN) posted briefing documents for its advisory committee meeting on Drisapersen for treatment of DMD.